Why Gilead Stock's Newest Drug Approval Isn't A Gamechanger

Gilead gains FDA approvela for its first cancer drug Zydelig, which will compete against Johnson & Johnson and Pharmacyclics' Imbruvica.

Topics:  fda   zydelig    johnson   pharmacyclics   imbruvica   johnson   gilead   drug   
BING NEWS:
  • Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
    In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, ...
    04/17/2024 - 1:00 am | View Link
  • Pfizer's Innovative Drug Pipeline Provides Ample Reason To Buy It Here
    COVID era, emphasizing innovation, oncology, and AI in drug development for potential growth. Learn more on PFE stock here.
    04/12/2024 - 8:30 am | View Link
  • 7 Diabetes and Weight Loss Drug Stocks for 2024
    The diabetes and weight loss prescription drug market shows no sign of thinning out anytime soon. Tackling the obesity problem head-on has been tried before with fad diets and ...
    04/9/2024 - 1:00 am | View Link
  • Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
    Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this HIV and hepatitis C drugmaker have returned -1.2% over ...
    04/2/2024 - 12:59 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News